Enriched circulating and tumor-resident TGF-β+ regulatory B cells in patients with melanoma promote FOXP3+ Tregs

Autor: Robert J Harris, Zena Willsmore, Roman Laddach, Silvia Crescioli, Jitesh Chauhan, Anthony Cheung, Anna Black, Jenny L. C. Geh, Alastair D MacKenzie Ross, Ciaran Healy, Sophia Tsoka, James Spicer, Katie E Lacy, Sophia N Karagiannis

Publikováno v: OncoImmunology, Vol 11, Iss 1 (2022)

B cells are emerging as key players of anti-tumor adaptive immune responses. We investigated regulatory and pro-inflammatory cytokine-expressing B cells in patients with melanoma by flow cytometric intracellular cytokine, CyTOF, transcriptomic, immun

Externí odkaz: https://doaj.org/article/5ee960605c5a4a89bebd0943b4e44eca

BRAF inhibitors and their immunological effects in malignant melanoma

Autor: Rebecca Adams, Jack E M Coumbe, Ben G T Coumbe, Jennifer Thomas, Zena Willsmore, Marija Dimitrievska, Monica Yasuzawa-Parker, Maximilian Hoyle, Suhaylah Ingar, Jenny L C Geh, Alastair D MacKenzie Ross, Ciaran Healy, Sophie Papa, Katie E Lacy, Sophia N Karagiannis

Publikováno v: Adams, R, Coumbe, J E M, Coumbe, B G T, Thomas, J, Willsmore, Z, Dimitrievska, M, Yasuzawa-Parker, M, Hoyle, M, Ingar, S, Geh, J, MacKenzie Ross, A, Healy, C, Papa, S, Lacy, K E & Karagiannis, S N 2022, ' BRAF inhibitors and their immunological effects in malignant melanoma ', Expert Review Of Clinical Immunology, vol. 18, no. 4, pp. 347-362 . https://doi.org/10.1080/1744666X.2022.2044796

Introduction: The treatment of cutaneous melanoma has been revolutionized by the development of small-molecule inhibitors targeting the MAPK pathway, including inhibitors of BRAF (BRAFi) and MEK (MEKi), and immune checkpoint blockade antibodies, occu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ab9be0d9ed21e170e39875d482bfb4
https://pubmed.ncbi.nlm.nih.gov/35195495

P266 IL-4/13 inhibitor dupilumab associated with new onset peripheral axial spondyloarthritis in patients with atopic dermatitis

Autor: Zena Willsmore, Bina Menon, Catherine H. Smith, R T Woolf, Andrew Pink, Catherine D Hughes, Bruce Kirkham

Publikováno v: Rheumatology. 59

Background Dupilumab is a recombinant human monoclonal antibody that inhibits signalling of interleukin-4 and interleukin-13. It has NICE approval for use in patients with moderate to severe atopic eczema who have failed at least one standard therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e94d8fd1b178020cdb1170a0f77e8d0a
https://doi.org/10.1093/rheumatology/keaa111.259

BRAF inhibitors and their immunological effects in malignant melanoma.

Autor: Adams, Rebecca, Coumbe, Jack E M, Coumbe, Ben G T, Thomas, Jennifer, Willsmore, Zena, Dimitrievska, Marija, Yasuzawa-Parker, Monica, Hoyle, Maximilian, Ingar, Suhaylah, Geh, Jenny L C, MacKenzie Ross, Alastair D, Healy, Ciaran, Papa, Sophie, Lacy, Katie E, Karagiannis, Sophia N

Publikováno v: Expert Review of Clinical Immunology; Apr2022, Vol. 18 Issue 4, p347-362, 16p

O20 Advanced melanoma is associated with distinct circulating B-cell profiles enriched with immunoregulatory and autoreactive features.

Autor: Willsmore, Zena, Crescioli, Silvia, Booth, Lucy, Laddach, Roman, Yorke, Rozalyn, Harris, Robert, Chauhan, Jitesh, Chenoweth, Alicia, Adams, Rebecca, Osborn, Gabriel, Di Meo, Ashley, Prassas, Ioannis, Geh, Jenny L C, Patel, Akshay J, Middleton, Gary W, Ross, Alastair D MacKenzie, Healey, Ciaran, Diamandis, Eleftherios P, Sinha, Khushboo, Wu, Yin

Publikováno v: British Journal of Dermatology; Jul2023, Vol. 189 Issue 1, pe12-e13, 2p